Literature DB >> 6291839

Effects of cimetidine and ranitidine on steady-state propranolol kinetics and dynamics.

I W Reimann, U Klotz, J C Frölich.   

Abstract

The influence of cimetidine (1000 mg daily, one day oral pretreatment) and ranitidine (300 mg daily by mouth, 1 and 6 days pretreatment) on steady-state propranolol (160 mg sustained-release capsule, once daily) plasma levels (Psss) and dynamic beta-blocker effects was assessed by bicycle ergometer exercise and isoproterenol sensitivity test in five normal subjects. During the 3 hr of the dynamic tests Psss were elevated from 25% to 67% by cimetidine, whereas Pss was unchanged by ranitidine. The estimated hepatic blood flow (EHBF) as calculated from indocyanine green (ICG) plasma clearance was only slightly reduced by 15 +/- 23% (mean +/- SD, n = 4) after one oral dose of 150 mg ranitidine and showed substantial intersubject variability. Dynamic parameters, like propranolol-induced heart rate and blood pressure changes under physical exercise or during the isoproterenol sensitivity test, were not influenced by ranitidine or cimetidine. Since our study was performed on normal subjects with relatively low propranolol doses these results do not rule out the risk of severe reinforcement of beta-adrenergic receptor blocking effects if propranolol and cimetidine are taken together by patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6291839     DOI: 10.1038/clpt.1982.232

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

Review 1.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

2.  Drug interactions through binding to cytochrome p 450: the experience with h2-receptor blocking agents.

Authors:  U Klotz; I W Reimann
Journal:  Pharm Res       Date:  1984-03       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol.

Authors:  T Tateishi; H Nakashima; T Shitou; Y Kumagai; K Ohashi; S Hosoda; A Ebihara
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Influence of ranitidine on plasma metoprolol concentrations.

Authors:  H Spahn; E Mutschler; W Kirch; H Hoensch; E E Ohnhaus; H D Janisch
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-17

6.  The effect of ranitidine and cimetidine on imipramine disposition.

Authors:  B G Wells; J A Pieper; T H Self; C F Stewart; S L Waldon; L Bobo; C Warner
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 7.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

8.  Cimetidine-induced alterations in desipramine plasma concentrations.

Authors:  J D Amsterdam; D J Brunswick; L Potter; M J Kaplan
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 9.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

Review 10.  Interactions and non-interactions with ranitidine.

Authors:  W Kirch; H Hoensch; H D Janisch
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.